CSIMarket
 


Revance Therapeutics Inc   (RVNC)
Other Ticker:  
 
 

RVNC's Capital Expenditures Growth by Quarter and Year

Revance Therapeutics Inc 's Capital Expenditures results by quarter and year




RVNC Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 1.78 1.29 4.36 257.41
III Quarter September 4.50 1.00 1.00 0.78
II Quarter June 0.00 0.00 0.98 0.57
I Quarter March 0.87 1.46 4.04 0.66
FY   7.15 3.75 10.38 259.42



RVNC Capital Expenditures fourth quarter 2023 Y/Y Growth Comment
Revance Therapeutics Inc reported Capital Expenditures improvement of 37.91% year on year in the fourth quarter 2023, to $ 1.78 millions, this is lower than Revance Therapeutics Inc 's recent average Capital Expenditures surge of 1322.5%.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 35 other companies have achieved higher Capital Expenditures growth. While Revance Therapeutics Inc ' s Capital Expenditures rise of 37.91% ranks overall at the positon no. 1192 in the fourth quarter 2023.




RVNC Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December 37.91 % -70.41 % -98.31 % 88662.07 %
III Quarter September 350 % 0 % 28.21 % -47.3 %
II Quarter June - - 71.93 % 50 %
I Quarter March -40.41 % -63.86 % 512.12 % -39.45 %
FY   90.64 % -63.87 % -96 % 7906.79 %

Financial Statements
Revance Therapeutics Inc 's fourth quarter 2023 Capital Expenditures $ 1.78 millions RVNC's Income Statement
Revance Therapeutics Inc 's fourth quarter 2022 Capital Expenditures $ 1.29 millions Quarterly RVNC's Income Statement
New: More RVNC's historic Capital Expenditures Growth >>


RVNC Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -60.47 % 29 % 336 % 32901.28 %
III Quarter September - - 2.04 % 36.84 %
II Quarter June - - -75.74 % -13.64 %
I Quarter March -32.56 % -66.51 % -98.43 % 127.59 %
FY (Year on Year)   90.64 % -63.87 % -96 % 7906.79 %




Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #144
Overall #1192

Capital Expenditures Y/Y Growth Statistics
High Average Low
11373.52 % 1322.5 % -97.62 %
(Sep 30 2021)   (Sep 30 2022)
Capital Expenditures fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #144
Overall #1192
Capital Expenditures Y/Y Growth Statistics
High Average Low
11373.52 % 1322.5 % -97.62 %
(Sep 30 2021)   (Sep 30 2022)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Revance Therapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
33029.21 % 964.26 % -100 %
(Dec 31 2020)  


RVNC's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Revance Therapeutics Inc realized fall in Capital Expenditures from the third quarter by -60.47% to $ 1.78 millions, from $ 4.50 millions achived in the previous quarter.

Even periodic factors which usually energize IV. Quarter 2023 results, it simply could not be sufficient to recover Major Pharmaceutical Preparations's company outcome, George  Hall, a business contributor said.

Within Major Pharmaceutical Preparations industry 56 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Revance Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1525.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #57
Healthcare Sector #194
Overall #1525
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #57
Healthcare Sector #194
Overall #1525
Capital Expenditures Q/Q Growth Statistics
High Average Low
33029.21 % 964.26 % -100 %
(Dec 31 2020)  


RVNC's IV. Quarter Q/Q Capital Expenditures Comment
In the IV. Quarter 2023 Revance Therapeutics Inc realized fall in Capital Expenditures from the previous quarter by -60.47% to $ 1.78 millions, from $ 4.50 millions declared a quarter before.

Even cyclical circumstance were not able to rescue the IV. Quarter for the Revance Therapeutics Inc , George  Hall, a business contributor pointed out, he sees further challenges down the road for RVNC.

Within Major Pharmaceutical Preparations industry 56 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Revance Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1525.


Revance Therapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 3.21
Y / Y Capital Expenditures Growth (TTM) - - - - -69.06 %
Year on Year Capital Expenditures Growth Overall Ranking # 1245 # 0 # 0 # 0 # 2399
Seqeuential Capital Expenditures Change (TTM) - - - - -48.88 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1192 # 0 # 0 # 0 # 1902




Cumulative Capital Expenditures growth Comment
In the Dec 31 2023 period, Revance Therapeutics Inc 's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

In the Healthcare sector 157 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 1245.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
11373.52 %
1322.5 %
-97.62 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 36
Healthcare Sector # 158
Overall # 1245

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
11373.52 %
1322.5 %
-97.62 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 36
Sector # 144
S&P 500 # 1192
Cumulative Capital Expenditures growth Comment
In the Dec 31 2023 period, Revance Therapeutics Inc 's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

In the Healthcare sector 157 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 1245.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
11373.52 %
1322.5 %
-97.62 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 36
Healthcare Sector # 158
Overall # 1245

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
11373.52 %
1322.5 %
-97.62 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 36
Sector # 144
S&P 500 # 1192




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
RVNC's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for RVNC's Competitors
Capital Expenditures Growth for Revance Therapeutics Inc 's Suppliers
Capital Expenditures Growth for RVNC's Customers

You may also want to know
RVNC's Annual Growth Rates RVNC's Profitability Ratios RVNC's Asset Turnover Ratio RVNC's Dividend Growth
RVNC's Roe RVNC's Valuation Ratios RVNC's Financial Strength Ratios RVNC's Dividend Payout Ratio
RVNC's Roa RVNC's Inventory Turnover Ratio RVNC's Growth Rates RVNC's Dividend Comparisons



Companies with similar Capital Expenditures fall for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Perrigo Company Plc65.84%$ 65.839 millions
Regeneron Pharmaceuticals Inc 65.18%$ 65.177 millions
Anaptysbio Inc 60.00%$ 60.000 millions
Cadre Holdings Inc 59.32%$ 59.319 millions
Co diagnostics Inc 58.40%$ 58.403 millions
Macrogenics Inc 57.76%$ 57.761 millions
Caribou Biosciences Inc 56.28%$ 56.280 millions
Privia Health Group Inc 53.33%$ 53.333 millions
National Healthcare Corp52.58%$ 52.581 millions
Ani Pharmaceuticals Inc52.10%$ 52.101 millions
Avantor Inc 50.60%$ 50.595 millions
Bausch Health Companies Inc 50.00%$ 50.000 millions
Gh Research Plc49.25%$ 49.254 millions
Cryoport inc 44.64%$ 44.636 millions
Hologic Inc43.67%$ 43.671 millions
Viemed Healthcare Inc 42.59%$ 42.588 millions
Laboratory Corporation Of America Holdings41.82%$ 41.815 millions
Livanova Plc41.44%$ 41.439 millions
Revance Therapeutics Inc 38.12%$ 38.121 millions
Entrada Therapeutics Inc 37.85%$ 37.853 millions
Beigene ltd 37.54%$ 37.536 millions
Inari Medical Inc 34.98%$ 34.983 millions
Henry Schein Inc34.48%$ 34.483 millions
Healthcare Services Group Inc 34.18%$ 34.176 millions
Veracyte inc 33.39%$ 33.387 millions
Haemonetics Corporation32.32%$ 32.324 millions
Steris Plc29.53%$ 29.533 millions
Organon and Co 28.57%$ 28.571 millions
Brookdale Senior Living Inc 26.22%$ 26.219 millions
Boston Scientific Corporation25.94%$ 25.943 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com